PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34558242-15	2021	CONCLUSION: EA, metformin and EA plus metformin can improve cognitive ability and relieve SP formation in cerebral cortex and hippocampus in AD mice, which may be associated with their functions in down-regulating the expression of betaACE1 and up-regulating the expression of IDE.	Metformin	16-25	insulin degrading enzyme	Mus musculus	277-280	
34311050-0	2021	Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.	Metformin	0-9	insulin degrading enzyme	Mus musculus	68-92	
34311050-9	2021	Compared with controls, metformin-treated APP23-ob/ob mice had significantly reduced Abeta levels in the cerebral cortex (p < .05) and hippocampus (p < .05) and increased levels of IDE in the hippocampus (p < .01).	Metformin	24-33	insulin degrading enzyme	Mus musculus	181-184	
34311050-10	2021	Our results indicate that metformin attenuates the severity of CAA by enhancing Abeta-cleaving IDE expression.	Metformin	26-35	insulin degrading enzyme	Mus musculus	95-98	
34558242-15	2021	CONCLUSION: EA, metformin and EA plus metformin can improve cognitive ability and relieve SP formation in cerebral cortex and hippocampus in AD mice, which may be associated with their functions in down-regulating the expression of betaACE1 and up-regulating the expression of IDE.	Metformin	38-47	insulin degrading enzyme	Mus musculus	277-280	
32377293-0	2020	Metformin Ameliorates Abeta Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer"s Disease.	Metformin	0-9	insulin degrading enzyme	Mus musculus	41-65	
32377293-5	2020	In this study, we tried to figure out whether metformin could activate insulin-degrading enzyme (IDE) to ameliorate Abeta-induced pathology.	Metformin	46-55	insulin degrading enzyme	Mus musculus	71-95	
32377293-5	2020	In this study, we tried to figure out whether metformin could activate insulin-degrading enzyme (IDE) to ameliorate Abeta-induced pathology.	Metformin	46-55	insulin degrading enzyme	Mus musculus	97-100	
32377293-13	2020	Metformin increased the protein levels of p-AMPK and IDE in the brain of APP/PS1 mice, which might be the key mechanism of metformin on AD.	Metformin	0-9	insulin degrading enzyme	Mus musculus	53-56	
32377293-13	2020	Metformin increased the protein levels of p-AMPK and IDE in the brain of APP/PS1 mice, which might be the key mechanism of metformin on AD.	Metformin	123-132	insulin degrading enzyme	Mus musculus	53-56	
32538851-8	2020	DNLA and metformin treatments decreased amyloid-beta1-42, AbetaPP, PS1, and BACE1, while increasing IDE and neprilysin for Abeta clearance.	Metformin	9-18	insulin degrading enzyme	Mus musculus	100-103